Opaleye Management Has Lifted By $900,000 Its Momenta Pharmaceuticals (MNTA) Holding; Novavax Has 1.26 Sentiment

January 13, 2018 - By Nellie Frank

Opaleye Management Inc increased Momenta Pharmaceuticals Inc (MNTA) stake by 11.11% reported in 2017Q3 SEC filing. Opaleye Management Inc acquired 50,000 shares as Momenta Pharmaceuticals Inc (MNTA)’s stock declined 18.16%. The Opaleye Management Inc holds 500,000 shares with $9.25 million value, up from 450,000 last quarter. Momenta Pharmaceuticals Inc now has $1.20B valuation. The stock increased 10.14% or $1.45 during the last trading session, reaching $15.75. About 907,729 shares traded or 22.71% up from the average. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 54.42% since January 13, 2017 and is uptrending. It has outperformed by 37.72% the S&P500.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $520.40 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

Investors sentiment decreased to 1.73 in Q3 2017. Its down 0.25, from 1.98 in 2017Q2. It turned negative, as 16 investors sold MNTA shares while 29 reduced holdings. 16 funds opened positions while 62 raised stakes. 70.23 million shares or 2.61% more from 68.45 million shares in 2017Q2 were reported. Goldman Sachs Group owns 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 539,849 shares. D E Shaw & invested in 0.04% or 1.47M shares. Automobile Association owns 41,145 shares or 0% of their US portfolio. Bnp Paribas Arbitrage reported 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Blackrock owns 10.39 million shares. Principal Fincl Inc has 0.01% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Comml Bank Of Montreal Can reported 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Primecap Management Ca holds 0.04% or 2.84 million shares. 15,811 are owned by Public Employees Retirement Association Of Colorado. Ameriprise Fin stated it has 0.01% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Missouri-based Stifel Financial has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Moreover, Pacad Ltd has 0.01% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 2,000 shares. Ubs Asset Mgmt Americas owns 28,496 shares for 0% of their portfolio. Ftb Incorporated reported 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). The Pennsylvania-based Vanguard Group Inc has invested 0.01% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Among 12 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. Momenta Pharmaceuticals had 27 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has “Overweight” rating by JP Morgan on Friday, November 13. The stock has “Hold” rating by Stifel Nicolaus on Thursday, October 5. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has “Equal-Weight” rating given on Monday, May 22 by Barclays Capital. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has “Sell” rating given on Wednesday, September 7 by Maxim Group. Barclays Capital maintained the shares of MNTA in report on Tuesday, January 31 with “Overweight” rating. The rating was upgraded by Barclays Capital to “Overweight” on Tuesday, October 11. The rating was initiated by Barclays Capital on Monday, November 23 with “Equal-Weight”. On Thursday, August 3 the stock rating was maintained by Maxim Group with “Sell”. The firm has “Outperform” rating given on Wednesday, May 4 by Leerink Swann. Aegis Capital initiated Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Tuesday, November 22 with “Hold” rating.

Since August 2, 2017, it had 0 buys, and 10 insider sales for $1.49 million activity. Leicher Bruce sold $5,810 worth of stock or 350 shares. $3,400 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by WHEELER CRAIG A on Wednesday, August 2. 821 shares were sold by Kaundinya Ganesh Venkataraman, worth $12,479. $72,050 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by Stoner Elizabeth.

Bb Biotech Ag holds 0.26% of its portfolio in Novavax, Inc. for 8.33 million shares. Gsa Capital Partners Llp owns 1.12 million shares or 0.09% of their US portfolio. Moreover, Chicago Equity Partners Llc has 0.04% invested in the company for 1.07 million shares. The Maryland-based Rock Springs Capital Management Lp has invested 0.04% in the stock. Baker Bros. Advisors Lp, a New York-based fund reported 2.00 million shares.

Since January 1, 0001, it had 0 buys, and 1 sale for $184,870 activity.

Ratings analysis reveals 14% of Novavax’s analysts are positive. Out of 7 Wall Street analysts rating Novavax, 1 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $1.5 while the high is $12.0. The stock’s average target of $5.17 is 221.12% above today’s ($1.61) share price. NVAX was included in 7 notes of analysts from September 16, 2016. The stock of Novavax, Inc. (NASDAQ:NVAX) earned “Neutral” rating by Chardan Capital Markets on Tuesday, September 20. On Friday, September 16 the stock rating was downgraded by Wedbush to “Neutral”. FBR Capital maintained the stock with “Outperform” rating in Friday, September 16 report. The rating was downgraded by Citigroup on Friday, September 16 to “Neutral”. The stock of Novavax, Inc. (NASDAQ:NVAX) earned “Neutral” rating by Ladenburg Thalmann on Friday, September 16. On Friday, September 16 the stock rating was downgraded by JP Morgan to “Neutral”. The stock has “Neutral” rating by Piper Jaffray on Friday, September 16.

Analysts await Novavax, Inc. (NASDAQ:NVAX) to report earnings on February, 26. They expect $-0.15 earnings per share, up 28.57% or $0.06 from last year’s $-0.21 per share. After $-0.15 actual earnings per share reported by Novavax, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>